Regeneron Pharmaceuticals Inc (REGN): Plew Daniel P Van , EVP & General Mgr Industrial O of Regeneron Pharmaceuticals Inc sold 4,413 shares on May 18, 2016. The Insider selling transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were sold at $385.77 per share for a total value of $1,702,403.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 7, 2016, Joseph L Goldstein (director) sold 2,000 shares at $425.00 per share price.On Jan 14, 2016, Sanofi (10% owner) purchased 83,938 shares at $463.51 per share price.Also, On Dec 29, 2015, Douglas S Mccorkle (VP Controller and Asst Treasur) sold 3,954 shares at $552.08 per share price.On Dec 11, 2015, Michael S Brown (director) sold 3,000 shares at $545.37 per share price.
Shares of Regeneron Pharmaceuticals Inc (REGN) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -6.98 points or -1.79% at $383.3 with 12,56,175 shares getting traded. Post opening the session at $387.12, the shares hit an intraday low of $379.33 and an intraday high of $394.01 and the price vacillated in this range throughout the day. The company has a market cap of $40,277 M and the number of outstanding shares has been calculated to be 10,50,78,593 shares. The 52-week high of Regeneron Pharmaceuticals Inc is $605.9299 and the 52-week low is $348.96.
Company has been under the radar of several Street Analysts.Regeneron Pharmaceuticals Inc is Downgraded by Wells Fargo to Market Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Apr 20, 2016.Regeneron Pharmaceuticals Inc is Reiterated by Sun Trust Rbsn Humphrey to Neutral while Lowering the Price Target of the company shares to $ 410 from a previous price target of $450 . The Rating was issued on Mar 17, 2016.Regeneron Pharmaceuticals Inc is Downgraded by Chardan Capital Markets to Sell while Lowering the Price Target of the company shares to $ 325 from a previous price target of $375 . Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Mar 16, 2016.Regeneron Pharmaceuticals Inc is Initiated by Gabelli & Co to Buy and the brokerage firm has set the Price Target at $574. The Rating was issued on Mar 15, 2016.Regeneron Pharmaceuticals Inc is Initiated by Sun Trust Rbsn Humphrey to Neutral and the brokerage firm has set the Price Target at $450. The Rating was issued on Mar 3, 2016.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.